IDH1 and cholangiocarcinoma: To the best of our knowledge, our study is the first, outside of clinical trials and small case series, to confirm the efficacy and safety of ivosidenib as second and further line treatment in a large international cohort of patients with advanced IDH1 mutant CCA and to provide a comparison to the efficacy of second‐line chemotherapy, designed to fill the previously mentioned gaps.